Company intelligence / Profile preview

Prolexys Pharmaceuticals

Salt Lake City, Utah, United Statesprolexys.com ↗

Ownership: Private
Development stage: Other

Overview

Prolexys Pharmaceuticals developed a proteomics-driven drug discovery platform focused on identifying novel targets for small molecule therapeutics in oncology. Its lead candidate PRLX93936 entered Phase I trials for advanced solid tumors around the late '00s. The company also pursued backup molecules and additional preclinical programs targeting various cancers. No recent clinical results or updates are available since that period.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PRLX 93936

Partnerships

No major pharma partnerships disclosed; primary investor Friedli Corporate Finance supported development efforts.

Beyond the preview

Go deeper on Prolexys Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolexys Pharmaceuticals.